<DOC>
	<DOCNO>NCT00003193</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . PURPOSE : Phase I/II trial study effectiveness paclitaxel radiation therapy plus chemoprotection amifostine treat patient stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Paclitaxel Radiation Therapy Plus Chemoprotection With Amifostine Treating Patients With Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose paclitaxel amifostine radiotherapy patient stage III IV head neck cancer . - Determine toxic effect complication regimen term mucositis reduction patient . - Determine complete response rate progression-free survival patient treat regimen . - Determine whether amifostine modulates plasma pharmacokinetics paclitaxel patient . OUTLINE : This dose-escalation study paclitaxel without amifostine . Patients receive paclitaxel IV day 1 , 8 , 15 , 29 , 36 , 43 total 3-6 dos . Patients also undergo radiotherapy twice daily 6 week , except day paclitaxel give . Cohorts 2-5 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose 2-3 patient experience dose-limiting toxicity . An additional 10 patient treated MTD . After determination MTD paclitaxel , subsequent patient also receive amifostine IV 15 minute day 1 , 8 , 29 , 36 radiotherapy day 2-5 30-33 . Determination MTD drug combination carry paclitaxel alone . At 4 8 week last treatment radiotherapy , patient undergo CT scan determine response . Patients residual mass undergo neck dissection . Patients complete partial response primary site follow without surgery . Patients follow every 6 month . PROJECTED ACCRUAL : A maximum 37 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV squamous cell head neck cancer T34 , N03 , M0 PATIENT CHARACTERISTICS : Age : 18 Performance Status : ECOG 02 Life Expectancy : Not specify Hematopoietic : WBC least 2,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin great 3.0 mg/dL SGOT great 3 time upper limit normal Renal : Creatinine great 3.0 mg/dL Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent betaadrenergic block agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>oral complication</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>